T 0592/99 (Matrix-formulation/EURO-CELTIQUE) of 01.08.2002
- European Case Law Identifier
- ECLI:EP:BA:2002:T059299.20020801
- Date of decision
- 1 August 2002
- Case number
- T 0592/99
- Petition for review of
- -
- Application number
- 94303128.6
- IPC class
- A61K 31/135
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Controlled release formulation containing tramadol
- Applicant name
- Euro-Celtique S.A.
- Opponent name
- Krewel-Meuselbach GmbH
Nycomed DAK A/S
Bioglan Laboratories Ltd
Lannacher Heilmittel Ges.m.b.H.
Hexal Aktiengesellschaft
Arzneimittelwerk Dresden GmbH - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c) 1973European Patent Convention Art 112(1) 1973European Patent Convention Art 123(2) 1973European Patent Convention Art 123(3) 1973European Patent Convention Art 84 1973
- Keywords
- Subject-matter of claim 1 of the patent in suit as granted extends beyond the application as filed - claimed subject-matter covers products not originally disclosed - technical contribution according to G 0001/93
- Catchword
- In the view of the Board, in the typical example given in point 16 of the decision G 0001/93, the expression "inventive selection" in the phrase "where the limiting feature is creating an inventive selection not disclosed in the application as filed or otherwise derivable therefrom" cannot mean anything other than a potential (inventive) selection - obviously, an opponent cannot be requested to demonstrate the potential character of the selection without making or preventing itself from making a further selection invention (Reasons No. 2.5)
ORDER
For these reasons it is decided that:
The appeal is dismissed.